Second Circular and Provisional Conference Programme for IVW 2009

The Third International Conference on Influenza Vaccines for the World

IVW 2009 – 27-30 April 2009, Palais des Festivals et des Congres, Cannes Cedex, France

Scientific Advisory Panel

Nancy Cox (CDC, Atlanta, USA) · Klaus Stöhr (Novartis Vaccines, Germany) · John Wood (NIBSC, UK)
Valentine Delore (Sanofi-Pasteur, Lyon, France) · Rob Lambkin-Williams (Retroscreen Virology Ltd., London, UK)
Martin Meltzer (CDC, Atlanta, USA) · Dirk X. Poelaert (GSK Biologicals, Rixensart, Belgium)
Douglas Fleming (RCGP, Birmingham, UK) · Albert Osterhaus (Erasmus University, Rotterdam, The Netherlands)
Jim Robertson (NIBSC, Potters Bar, UK) · John S. Oxford (Queen Mary’s School of Medicine & Dentistry, London, UK)
Bram Palache (Solvay, The Netherlands)

Conference Scope

IVW 2009 will address the following important topics:

- Surveillance Issues / Burden of Disease · Immunological Issues
- Social / Political / Financial Issues Surrounding Influenza Vaccination · Novel Developments
- Production / Formulation Issues / Manufacturing Issues · Vaccine Usage / Targeting Strategies
- Influenza Vaccines / Adjuvants – Improvement Issues · Pandemic Preparedness Issues / Licensing Issues

The scientific programme will include keynote lectures, contributed papers, satellite symposia and poster presentations emphasising all aspects of ‘Influenza Vaccines’ and their usage and effectiveness.

Announcing a new one day IVW 2009 satellite symposium

Antivirals, Vaccines & Antibodies:
A Joint Approach to Seasonal & Pandemic Influenza

27 April 2009, Palais des Festivals et des Congres, Cannes Cedex, France

The imminent threat of an outbreak of pandemic influenza has focussed leading scientists attention on the planning and usage of antiviral drugs and vaccines in combination to mitigate and counter such an event.

AVPI 2009 is a one day satellite symposium that will precede IVW 2009.

The AVPI 2009 Conference Programme will include presentations from renowned world experts on the use of antiviral drugs, vaccines and antibodies, and the combined strategies that will be employed in the face of a worldwide influenza pandemic and seasonal influenza.

Closing date for poster abstract submissions Friday 13th March 2009

Register securely on-line at: www.meetingsmanagement.com/ivw_2009

*Sponsored by

*Sponsored by

*Image of Negative Staining of TEM of Influenza Virus courtesy of NIBSC, Potters Bar, UK
**SESSION 1: OVERVIEW**

Moderator: John Oxford  
(Retroscreen Virology Ltd., London, UK)

- The three pillars of influenza control: Vaccines, antivirals and non-pharmaceutical interventions  
  Arnold Monto (University of Michigan, USA)

- Public health options for use of antivirals and vaccines in a pandemic – an ECDC perspective  
  Angus Nicoll (European centre for Disease Prevention and Control, Stockholm, Sweden)

- Optimizing stockpiles: Basic concepts in determining vaccines and antivirals stockpile sizes  
  Martin I. Meltzer (CDC, Atlanta, Georgia, USA)

- Confronting an influenza pandemic with inexpensive generic agents: can it be done?  
  David Fedson (Sergy Haut, France)

Coffee Break

**SESSION 2: ANTIVIRALS**

Moderator: Arnold Monto  
(University of Michigan, USA)

- Antiviral resistance in influenza: How useful is a stockpile?  
  Maria Zambon (Health Protection Agency, London, UK)

- Antivirals developments – an update  
  Jonathan Van Tam (University of Nottingham, UK)

- Antiviral update – bridging from the management of seasonal and avian influenza virus infection to pandemic preparedness  
  David Reddy (F. Hoffman-La-Roche Ltd., Basel, Switzerland)

- Relenza presentation from GSK Biologicals  
  Richard South (GlaxoSmithKline) – TBC

Lunch Break

**SESSION 3: VACCINES**

Moderator: Jim Robertson  
(NIBSC, Potters Bar, UK)

- Seasonal and pre-pandemic influenza libraries  
  Othmar Engelhardt and John Wood (NIBSC, Potters Bar, UK)

- Generation of ancestral H5N1 influenza viruses as vaccine and diagnostic reagents  
  Mariette Ducatez, Justin Bahl, Evelyn Stigger, Yolanda Griffin, Ashley Webb, Yi Guan, Gavin Smith and Richard Webby (St Jude Children’s Research Hospital, Memphis, Tennessee, USA)

- Influenza experimental infection studies: The past, present and future  
  Rob Lambkin-Williams (Retroscreen Virology Ltd., London, UK)

- US pandemic planning – an update  
  Nancy Cox (CDC, Atlanta, Georgia, USA)

Discussion

Tea Break

**SESSION 4: ANTIBODIES & SUMMARY**

Moderator: John Oxford  
(Retroscreen Virology Ltd., London, UK)

- An influenza N1 neuraminidase-specific monoclonal antibody protects animal against live challenge with homologous H5N1 virus  
  Vidadi Yusibov (Fraunhofer USA, Newark, Delaware, USA)

- A unique class of protective human anti-M2 mAbs for pandemic influenza  
  Matthew Moyle (Spaltudaq Corporation, Seattle, Washington, USA)

- Perspectives of ‘Super catalytic antibodies (Antigenase)’ for prevention from the infection of influenza virus type A  
  Taizo Uda and Emi Hifumi (Oita University, Japan)

- Satellite Overview Presentation & Closing Discussion  
  John Oxford (Retroscreen Virology Ltd., London, UK)

Evening:

IVW 2009 Conference Registration
SESSION 1:
OPENING PLENARY SESSION
Moderator: Bram Palache (Solvay, Weesp, The Netherlands)

‘Applications of immunology to influenza vaccine development’
Andrew McMichael (University of Oxford, UK) – TBC

‘Social and scientific resilience during the 1918 pandemic: antivirals, masks and vaccines’
John Oxford (Retroscreen Virology Ltd., London, UK)

‘New technologies for meeting the global demand for pandemic influenza vaccines’
David Fedson (Sergy Haut, France)

‘Towards better influenza vaccines: Addressing current deficiencies’
Arnold Monto (University of Michigan, USA)

Coffee Break & Poster Set-Up

SESSION 2:
INFLUENZA VACCINE EFFECTIVENESS & SURVEILLANCE
Moderator: Martin I. Meltzer (CDC, Atlanta, Georgia, USA)

‘Influenza virus evolution’
Derek Smith (University of Cambridge, UK)

‘Influenza transmission – A challenging subject’
Ben Killingley (University of Nottingham, UK)

‘Influenza vaccine effectiveness estimated from routine virological surveillance data’
D. Fleming (Royal College of General Practitioners, Birmingham, UK) and N. Andrews, A. Bermingham, J. Ellis, E. Miller, R. Pebody and M. Zambon

‘Influenza vaccine effectiveness for reducing hospitalization in the elderly: 2 year cohort study’
Kirsten Nichol (University of Minnesota, Minneapolis, USA)

The Western Australian Influenza Vaccine Effectiveness Study (WAIVE): Successful implementation of paediatric influenza vaccination in a large metropolitan trial’
(Western Australia Dept of Health, East Perth, Australia)

‘Influenza vaccine effectiveness in working adults ages 50 to 64’
Kirsten Nichol (University of Minnesota, Minneapolis, USA)

Lunch Break, Exhibition & Posters

SESSION 3:
INFLUENZA VACCINE STOCKPILING & USAGE
Moderator: Douglas Fleming (RCGP, Birmingham, UK)

‘Economics and stockpiling: Some basic principles’
Martin I. Meltzer (CDC, Atlanta, Georgia, USA)

‘Influenza pandemic vaccines: stockpiles or pre-pandemic use’
Klaus Stohr
(Novartis Vaccines, Cambridge, Massachusetts, USA)

‘Influenza vaccine stockpiling’
Dirk Poelaert (GSK Biologicals, Rixensart, Belgium)

‘Flu Vaccine Manufacturers Presentation’
Luc Hessel (Sanofi Pasteur MSD, Lyon, France) – TBC

Tea Break, Exhibition & Posters

SESSION 4:
NOVARTIS VACCINES SATELLITE SYMPOSIUM

‘Technological Advances in Seasonal and Pandemic Influenza Vaccines’

Evening:
IVW 2009 Welcome Reception, Exhibition & Poster Session A

Poster Papers

Late poster paper submissions are invited and prospective authors should submit a one page abstract of their poster(s) to the Conference organizers (Meetings Management) for consideration. Please send your poster for the attention of John Herriot (Email: jherriot@meetingsmgmt.u-net.com) at Meetings Management. Late poster abstracts should be submitted by Friday 13th March 2009.
SESSION 5:
VACCINE IMMUNE RESPONSE
Moderator: Nancy Cox (CDC, Atlanta, Georgia, USA) – TBC

'Effects of priming with two doses of Clade 0 rH5 influenza vaccine on immune response to vaccination 9 years later with Clade 1 H5N1 vaccine'
(CDC, Atlanta, Georgia, USA)

SESSION 7:
VACCINATING PREGNANT WOMEN AND OTHER VULNERABLE POPULATIONS
Moderator: Carolyn B. Bridges (CDC, Atlanta, USA)

'Special Session
Speakers to be confirmed
Tea Break, Exhibition & Posters

SESSION 8:
H5N1 INFLUENZA VACCINES
Moderator: John Wood (NIBSC, Potters Bar, UK)

'A Phase II, randomized, controlled, observer-blind, single-center study to evaluate the immunogenicity, safety and tolerability of two doses of MF59® – adjuvanted H5N1 influenza vaccine, AFLUNOV®, in subjects aged 6 months to 17 years'
Timo Vesikari (University of Tampere, Finland), Nicola Groth, Elena Fragapane (Novartis Vaccines, Siena, Italy), Sandrine Tilman (Novartis Vaccines, Amsterdam, The Netherlands) and Anke Hilbert (Novartis Vaccines & Diagnostics, GmbH & Co., Marburg, Germany)

SESSION 6:
GSK BIOLOGICALS SATELLITE SYMPOSIUM
'Title to be confirmed'

Lunch Break, Exhibition & Posters

SESSION 9:
BAXTER VACCINES SATELLITE SYMPOSIUM

'Vero cell derived whole virus H5N1 Vaccine: Safety, prime-boost and cross-neutralization data'

Venue:
The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/ivw_2009
SESSION 10:
ADJUVANTS, VLPS & DELIVERY
Moderator: Rob Lambkin-Williams
(Retroscreen Virology Ltd., London, UK)

'New generation adjuvants for improved influenza vaccines'
Derek O'Hagan
(Novartis Vaccines, Cambridge, Massachusetts, USA)

'Novel adjuvant and delivery systems for seasonal and pandemic influenza'
Alex von Gabain (Intercell AG, Vienna, Austria)

'VLP-based influenza vaccines'
Martin Bachmann (Cytos Biotechnology, Zurich, Switzerland)

'Innovative H5N1 virus-like particles: a unique combination of product and manufacturing solution'
(Medicago Inc., Quebec, Canada)

'Nasal vaccination'
Ulf Schroder (Eurocine AB, Stockholm, Sweden)

Coffee Break, Exhibition & Posters

SESSION 11:
SANOFI PASTEUR SATELLITE SYMPOSIUM
'Seasonal influenza immunization using a new micro-injection intra-dermal vaccine: an attractive avenue to improve flu vaccination'

Lunch Break, Exhibition & Posters

SESSION 12:
NOVEL & NEW VACCINES DEVELOPMENT
Moderator: Jim Robertson (NIBSC, Potters Bar, UK)

'Clinical trials of an influenza vaccine designed to induce cross-subtype immunity'
Sarah C. Gilbert (Jenner Institute, University of Oxford, UK)

'Plant-produced HA from A/Indonesia/05/05 protects ferrets against homologous challenge infection'
Vidadi Yusibov et al.
(Fraunhofer USA, Newark, Delaware, USA)

'Potent influenza vaccines produced efficiently in E. Coli'
Alan Shaw (Vaxinnate Corporation, Cranbury, New Jersey, USA)

'A universal influenza vaccine: Generating broad immunity using an M2e/NP fusion protein'
Debbie Higgins
(Dynavax Technologies Inc., Berkeley, California, USA)

'Multimeric epitope-based universal vaccine against influenza'
Tammy Ben-Yedidia, E. Kate-Ilovitz and Y. Singer
(BiondVax Pharmaceuticals, Ness Ziona, Israel)

'Development of an oral vaccine for the Avian influenza virus'
V. Condelli, M.T. Lanorte, A. Vitti, M. Nuzzaci and P. Piazzolla
(University of Basilicata, Potenza, Italy)

'Optimizing downstream processing of replication-defective influenza virus vaccine'
M. Peterka, E. Maurer, M. Gassner, H. Seper, F. Gelhart, M. Banjec, M. Jarc, B. Lah, P. Kramberger, A. Strancar and T. Muster (Avir Green Hills Biotechnology, Vienna, Austria and BIA Separations, Ljubljana, Slovenia)

Tea Break & Poster Break Down

SESSION 13:
PANDEMIC VACCINES & RELATED ISSUES
Moderator: John Oxford
(Retroscreen Virology Ltd., London, UK)

'Novel generations of vaccines for pandemic influenza preparedness'
Albert Osterhaus
(Erasmus University, Rotterdam, The Netherlands)

'Assessment of pandemic vaccines: How close are we to a correlate of protection?'
Maria Zambon (Health Protection Agency, London, UK)

'Cardiovascular burden of influenza: Implications for the next pandemic'
Mohammad Madjid
(Texas Heart Institute, Houston, Texas, USA)

CLOSING PLENARY:
'Pandemic influenza vaccines: What is the plan and what does the future hold?'
John Wood (NIBSC, Potters Bar, UK)

Conference Close, Exhibition and Poster Breakdown

Please note that this provisional programme is correct at the time of printing but may be subject to changes before the final programme production.
'Generation of ancestral H5N1 influenza viruses as vaccine and diagnostic reagents'
Mariette Ducatez, Justin Bahl, Evelyn Stigger, Yolanda Griffin, Ashley Webb, Gavin Smith and Richard Webby
(St Jude Children’s Research Hospital, Memphis, Tennessee, USA)

'Impaired immune responses in the lungs of aged mice following influenza infection'
Franklin R. Toapanta and Ted M. Ross
(University of Pittsburgh, Pennsylvania, USA)

'Surveillance, molecular characterization and antiviral resistance study of human influenza A virus in Turkey during 2007–2008 season'
Meral A. Ciblak et al. (Istanbul University, Turkey)

'Novel vaccine candidates and delivery systems for influenza'
Gunnveig Grodeland et al. (University of Oslo, Norway)

'Immunomodulatory function(s) of attenuated Bordetella pertussis provides cross-protection against lethal challenge with a mouse-adapted H3N2 influenza A virus'
Sylvie Alonso (National University of Singapore, Singapore)

'Evidence of influenza or influenza-like illness preceding acute coronary syndrome from Northern Thailand'
Sunate Chuenkitmongkol et al. (Sanofi Pasteur, Thailand)

'Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections'
Yoichi Furuya et al.
(Australian National University, ACT, Australia)

'The contribution of seasonal influenza to childhood pneumonia in a sub-tropical urban setting and the potential effect of influenza vaccine on pneumonia morbidity and hospitalisation'
W. Abdullah Brooks (ICDDR, Dhaka, Bangladesh)

'Influenza vaccination among patients and healthcare workers during the 2006–2007 winter at the Edouard Herriot University Hospital, Lyon, France'
Nicolas Voirin et al. (Universite de Lyon, France)

Philippe Vanhems et al. (Universite de Lyon, France)

'Plant–produced vaccines against highly pathogenic avian influenza A virus, H5N1'
Elizabeth Mortimer et al. (University of Cape Town, South Africa)
REGISTRATION

Delegates should register for IVW 2009 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (payment in £ Pounds Sterling) should be sent to the IVW 2009 Conference Manager – Caroline Sumner at Meetings Management. The IVW 2009 Conference Registration Desk will be open from 8.00am on Monday 27th April 2009. Delegates can also register securely on-line at: www.meetingsmanagement.com/ivw_2009

VENUE & ACCOMMODATION

The venue for IVW 2009 is the Palais des Festivals et des Congres, Cannes Cedex, France.

The organizers have negotiated special discounted accommodation rates for IVW 2009 delegates at the following hotel:

LE GRAND HOTEL
45 La Croisette, BP 263, 06401 Cannes, France
Tel: +33 (0) 4 93 38 15 45 Fax: +33 (0) 4 93 68 97 45
Web: www.grand-hotel-cannes.com

For group bookings please contact the Conference Manager Caroline Sumner – contact details below.

DELEGATE PACK INSERT SERVICE

Company literature/brochures/conference brochures may be distributed to delegates as part of the documentation issued on arrival/registration. One insertion in the IVW 2009 delegate pack is priced at £425. Please make your booking and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Delegate Pack Insertion services at IVW 2009 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com)

PLEASE NOTE: Literature for distribution to IVW 2009 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at IVW 2009. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAMME

The IVW 2009 Scientific Advisory Committee and the IVW 2009 Conference Organizers reserve the right to alter any part of the published conference programme if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The programme published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (abstract booklet, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization’s library up to date. The cost of providing this non-attendee package is £495 (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner IVW 2009 Conference Manager (details below).

IVW 2009 Conference Secretariat, Meetings Management
The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
Conference Manager: Caroline Sumner  Telephone: +44 (0)1483 427770  Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.u-net.com  Register securely on-line at: www.meetingsmanagement.com/ivw_2009
Please tick appropriate boxes and write clearly in BLOCK CAPITALS or type.

Surname .......................................................... Initials/First Name .......................................................... Title (Mr, Mrs, Dr, Prof etc.) ..........................................................

Organization ............................................... Full Address ..........................................................

.......................................................... Postcode ..........................................................

Country .................................................... Telephone .................................................... Fax ..........................................................

E-mail (plain type or print): ..........................................................

If you are an EC business please state your VAT registration number: ..........................................................

Disabled (please state any special needs): ..........................................................

Special diet (please state requirements): ..........................................................

(Delegates, please advise the conference office if you expect to be away during the period immediately prior to the conference and provide a forwarding address).

---

Registration Fees

<table>
<thead>
<tr>
<th>Speaker/Delegate Registration Fees: (NOTE THAT FEES ARE IN UK £ STERLING)</th>
<th>IZES. ADELEGEE REGISTRATION FORMS NOT DILY &amp; FULLY COMPLETED WILL NOT BE VALID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Four Days Joint Package (Symposium &amp; Conference) (Payment must be received before Friday 27 February 2009)</td>
<td>£1595.00</td>
</tr>
<tr>
<td>Speaker Registration (Submitted oral/poster papers) (Payment must be received before Friday 27 February 2009)</td>
<td>£595.00</td>
</tr>
<tr>
<td>One Day Antivirals/Vaccines Symposium (Payment must be received before Friday 27 February 2009)</td>
<td>£695.00</td>
</tr>
<tr>
<td>Three Days IVW 2009 Conference Registration (Payment must be received before Friday 27 February 2009)</td>
<td>£1195.00</td>
</tr>
<tr>
<td>Student Registration (Price on application, contact Conference Manager)</td>
<td></td>
</tr>
<tr>
<td>Delegate Pack Insert</td>
<td>£425.00</td>
</tr>
</tbody>
</table>

Late Rates – Payment received after Friday 27th February 2009

| Four Days Joint Package (Symposium & Conference) | £1695.00 |
| Speaker Registration (Submitted oral/poster papers) | £795.00 |
| One Day Antivirals/Vaccines Symposium | £795.00 |
| Three Days IVW 2009 Conference Registration | £1295.00 |

For those Unable to Attend

| Set(s) of IVW 2009 materials | @ £495.00 (per set) |

EARLY REGISTRATION IS ADVISED TO AVOID DISAPPOINTMENT

Total Amount Payable

---

Registration fees include admission to all conference sessions, exhibition, morning and afternoon refreshments and lunches on 27th, 28th, 29th and 30th April 2009 and the Welcome Reception.

---

Payment

I enclose a cheque for £ ............ made payable to Meetings Management. (Delegates registering from outside the UK must ensure that cheques are drawn on a London Bank. Please quote IVW 2009 on the reverse of the cheque.)

I have paid £ ............ by bank transfer. Send to Barclays Business Centre, Guildford Branch, PO Box 33, Guildford, Surrey GU1 3AN, UK. Collection account number: Meetings Management 0040614335, sorting code 20–35–35, IBAN Number: GB02BARC20–35–35 40614335. Delegates wishing to pay in Euros can transfer funds to account: Meetings Management 59179600, Bank Swift Address: BARCGB22, IBAN Number: GB91BARC20–35–35 59179600.

Please quote participants name on the transfer slip and IVW 2009. All transfer charges must be paid by the sender. Delegates paying by this method are requested to send the Conference Manager a copy of the bank transfer. Payments made by bank transfer must have £15.00 added to the total. PLEASE NOTE THAT IT WILL NOT BE POSSIBLE TO PAY REGISTRATION FEES BY BANK TRANSFER AFTER FRIDAY 27 MARCH 2009. LATE PAYMENT AFTER FRIDAY 27 MARCH 2009 MUST BE MADE BY CREDIT CARD (VISA/MASTERCARD).

I would like to pay £ ............ by credit card (VISA/MasterCard only accepted).

Card no. ............ CV2 code (3 digit security code) ............ Expiry date ............

Address to which card is registered ............

Signature ............ Date ............

Please remember that any remittance sent but not received by the time of the conference must be paid again at the Registration desk: we will refund you later. Cancellations received before Friday 20 March 2009 will be refunded in full less an administrative charge of £150 per person. Refunds will not be possible if a cancellation is received after Friday 20 March 2009. Substitutions can be made at any time prior to the conference. Please inform the Conference Manager of any changes. We strongly advise that delegates purchase travel insurance to cover any unforeseen circumstances and protect against loss of hotel deposits and registration fees.

---

IVW 2009 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom

Conference Manager: Caroline Sumner  Telephone: +44 (0)1483 427770  Fax: +44 (0)1483 428516

Email: csumner@meetingsmgmt.u-net.com  Register securely on-line at: www.meetingsmanagement.com/ivw_2009

VAT No. 591 617618